VSTM - Verastem GAAP EPS of -$1.02 misses by $0.21
2024-03-14 17:16:51 ET
More on Verastem
- Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
- Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy
- Verastem gets FDA fast track status for lung cancer drug combo
- Seeking Alpha’s Quant Rating on Verastem
- Historical earnings data for Verastem